Nasdaq Welcomes GENFIT S.A. (Nasdaq: GNFT) to The Nasdaq Stock Market
27 Março 2019 - 7:13PM
GENFIT S.A. (Nasdaq: GNFT), a late-stage clinical biopharmaceutical
company focused on discovering and developing drug candidates and
diagnostic solutions targeting liver diseases, in particular those
of metabolic origin, rang the Nasdaq MarketSite bell in Times
Square today in celebration of its initial public offering on The
Nasdaq Stock Market.
GENFIT is a leader in the field of nuclear
receptor-based drug discovery with a rich history and strong
scientific heritage spanning almost two decades. The company’s lead
product candidate, elafibranor, is in Phase 3 development for the
treatment of nonalcoholic steatohepatitis, or NASH, an indication
for which there are no approved drugs today, but which presents
significant market opportunity. In 2018, the company also announced
positive preliminary results from a Phase 2 clinical trial
evaluating elafibranor in primary biliary cholangitis, or PBC, a
severe liver condition. Furthermore, GENFIT is developing
non-invasive and easy-to-access diagnostic tools for NASH.
“Our decision to become public on Nasdaq is the
continuation of twenty years of strategic planning in the field of
metabolic and liver diseases, which have led us to grow and become
a late stage biotechnology company with a strong footprint in the
US,” commented Jean-François Mouney, Chairman and CEO, GENFIT. “Our
ambition is to further progress to commercialization of our main
compound in NASH, as millions of patients are still left with no
treatment option as of today. Our U.S. and European teams are also
working very hard to bring an easy-to-access diagnostic solution on
the market, for NASH patients to be identified as early as
possible, on a large scale. The ultimate goal is to limit
consequences of disease progression – cirrhosis, cancer,
cardiovascular diseases – and as such reduce the economic burden
associated with NASH. We’re now all set for the next few years and
after compelling top line Phase 2 data with elafibranor in PBC in
December 2018, we are now looking forward to our upcoming top line
Phase 3 data with elafibranor in NASH.”
“GENFIT is on their way to becoming a leader in
the development of innovative therapies and diagnostics in
metabolic and liver-related diseases,” said Nelson Griggs,
President of the Nasdaq Stock Exchange. “Their scientific and
clinical expertise, translational disease-driven approach and
strong bioinformatics capabilities have allowed them to build a
scientific platform through which they discover and develop drug
candidates and diagnostic tools. We are thrilled to welcome them to
Nasdaq’s family of the world’s most innovative companies.”
The information contained above is provided for
informational and educational purposes only, and nothing contained
herein should be construed as investment advice, either on behalf
of a particular security or an overall investment strategy.
Information about the company is provided by the company or comes
from the company’s public filings and is not independently verified
by Nasdaq. Neither Nasdaq nor any of its affiliates makes any
recommendation to buy or sell any security or any representation
about the financial condition of any company. Statements regarding
Nasdaq-listed companies are not guarantees of future performance.
Actual results may differ materially from those expressed or
implied. Past performance is not indicative of future results.
Investors should undertake their own due diligence and carefully
evaluate companies before investing. ADVICE FROM A SECURITIES
PROFESSIONAL IS STRONGLY ADVISED.
About NasdaqNasdaq (Nasdaq: NDAQ) is a leading
global provider of trading, clearing, exchange technology, listing,
information and public company services. Through its diverse
portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven
technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 100
marketplaces in 50 countries. Nasdaq is home to over 4,000 total
listings with a market value of approximately $12 trillion. To
learn more, visit business.nasdaq.com.
Media Relations Contact:
- Emily Pan
- (646) 441-5120
- emily.pan@nasdaq.com
|
- Bianca Fata
- (646) 441-5073
- bianca.fata@nasdaq.com
|
- NDAQG -
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/f90c2cb3-758c-4fbb-bf79-0b58f48ba099
Genfit (NASDAQ:GNFT)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Genfit (NASDAQ:GNFT)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024